Compare XBIT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | BWAY |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 578.5M |
| IPO Year | 2015 | 2011 |
| Metric | XBIT | BWAY |
|---|---|---|
| Price | $2.19 | $13.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 47.0K | ★ 107.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $11.77 |
| 52 Week High | $3.44 | $26.63 |
| Indicator | XBIT | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 40.31 |
| Support Level | N/A | $11.90 |
| Resistance Level | $2.46 | $14.83 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 5.56 | 3.85 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.